Cronos Group (US) (TSE:CRON)
NASDAQ:CRON
Want to see TSE:CRON full AI Analyst Report?
CRON Stock Chart & Stats
C$3.70
-C$0.05(-1.74%)
At close: 4:00 PM EST
C$3.70
-C$0.05(-1.74%)
Day’s Range― - ―
52-Week RangeC$2.54 - C$4.66
Previous CloseN/A
Volume78.08K
Average Volume (3M)194.22K
Market Cap
C$1.43B
Enterprise ValueC$243.30M
Total Cash (Recent Filing)C$822.44M
Total Debt (Recent Filing)C$1.31M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 11, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding373,662,050
10 Day Avg. Volume249,628
30 Day Avg. Volume194,220
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)0.92
Price to Sales (P/S)6.74
P/FCF Ratio6.63K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$5.25Price Target Upside41.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.06
Revenue Forecast (FY)C$192.57M
Bulls Say, Bears Say
Bulls Say
Financial HealthCronos Group has robust liquidity and an asset-light model which supports its operations.
Sales GrowthGrowth was strong in multiple markets, including a 57% increase in Israel and 183% in other countries.
Bears Say
Profitability UncertaintyThe timing of profitability is unclear, and the company is not expected to achieve positive adjusted EBITDA before 2026.
Regulatory ChallengesRegulatory challenges, including unclear US federal cannabis reform and changes to the Canadian Cannabis Act, are significant factors that negatively impact the stock's valuation.
Valuation PressureCronos Group's enterprise value is slightly negative, attributed to the lack of US reform and investor restrictions, which pressures the stock compared to its peers.
Cronos Group News
CRON FAQ
What was Cronos Group (US)’s price range in the past 12 months?
Cronos Group (US) lowest stock price was C$2.54 and its highest was C$4.66 in the past 12 months.
What is Cronos Group (US)’s market cap?
Cronos Group (US)’s market cap is C$1.43B.
When is Cronos Group (US)’s upcoming earnings report date?
Cronos Group (US)’s upcoming earnings report date is Aug 11, 2026 which is in 61 days.
How were Cronos Group (US)’s earnings last quarter?
Cronos Group (US) released its earnings results on May 11, 2026. The company reported C$0.056 earnings per share for the quarter, beating the consensus estimate of C$0.007 by C$0.049.
Is Cronos Group (US) overvalued?
According to Wall Street analysts Cronos Group (US)’s price is currently Undervalued.
Does Cronos Group (US) pay dividends?
Cronos Group (US) does not currently pay dividends.
What is Cronos Group (US)’s EPS estimate?
Cronos Group (US)’s EPS estimate is <0.01.
How many shares outstanding does Cronos Group (US) have?
Cronos Group (US) has 373,662,050 shares outstanding.
What happened to Cronos Group (US)’s price movement after its last earnings report?
Cronos Group (US) reported an EPS of C$0.056 in its last earnings report, beating expectations of C$0.007. Following the earnings report the stock price went up 8.069%.
Which hedge fund is a major shareholder of Cronos Group (US)?
Currently, no hedge funds are holding shares in TSE:CRON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cronos Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$5.25 (41.89% Upside)
C$5.25 (41.89% Upside)
Blogger Sentiment
Bullish
TSE:CRON Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days <0.1%
Last 30 Days <0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.34%
12-Months-Change
Fundamentals
Return on Equity
-0.19%
Trailing 12-Months
Asset Growth
1.58%
Trailing 12-Months
Company Description
Cronos Group (US)
Cronos Group Inc. functions as a diversified global cannabinoid enterprise. Within the United States, it manufactures, promotes, and distributes a variety of hemp-derived supplements and cosmetic products. These items are available under its Lord Jones and Happy Dance brands through online sales, traditional retail, and hospitality partner networks. The company also plays a significant role in the cultivation, production, and commercialization of cannabis and cannabis-infused products for both medicinal and adult-use sectors. Its comprehensive product offerings encompass dried cannabis flower, pre-rolled joints, edibles, concentrated forms, and cannabis extracts. These are distributed via wholesale partnerships and direct-to-consumer channels, prominently featuring its wellness platform, PEACE NATURALS, and its adult-use brand, Spinach. Moreover, Cronos Group exports dried cannabis and cannabis oils to international markets including Germany, Israel, and Australia. Established in 2012, the company maintains its corporate headquarters in Toronto, Canada.
CRON Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive tone driven by record annual and quarterly results, strong organic revenue growth (25% full year; Q4 +47%), product and brand momentum in Canada (Spinach, edibles, vapes) and robust international performance (Israel +52%, other international +68%). The company emphasized a strong balance sheet (no debt, $832M cash), disciplined capital allocation (share repurchases, modest CapEx) and strategic expansion via the accretive CanAdelaar acquisition. Near-term operational challenges tied to GrowCo expansion caused Q4 margin and adjusted EBITDA pressures as well as some shipment timing effects, but management expects these to normalize and views full-year 2025 margins (43%) as a reasonable run rate. Overall, highlights meaningfully outweigh the lowlights, with manageable operational issues and clear levers for margin recovery and growth.View all TSE:CRON earnings summariesCRON Stock 12 Month Forecast
Average Price Target
C$5.25
▲(41.89% Upside)
Technical Analysis
Canopy Growth
―
Curaleaf Holdings
―
Green Thumb Industries
―
Trulieve Cannabis
―
Cresco Labs
―
Options Prices
Currently, No data available
---